Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180657 | 1.00 | ATR (0.43) | ATRCYP17A1AAK1GSK3BDYRK1A | |
| SCHEMBL6180055 | 0.83 | NPC1 (0.40) | GSK3BMLYCDPIK3C3 | |
| SCHEMBL29640073 | 0.83 | ATR (0.53) | ATRCYP17A1AAK1GSK3BDYRK1A | |
| SCHEMBL27596021 | 0.83 | PIK3C3 (0.49) | JAK2JAK1TYK2PIK3C3 | |
| SCHEMBL14359967 | 0.83 | ATR (0.53) | ATRCYP17A1AAK1GSK3BDYRK1A | |
| SCHEMBL2080457 | 0.81 | KDM4D (0.47) | ATRCYP17A1GSK3BDYRK1AIRAK4 | |
| SCHEMBL29465812 | 0.81 | KDM4D (0.47) | ATRCYP17A1GSK3BDYRK1AIRAK4 | |
| SCHEMBL29626657 | 0.81 | CYP17A1 (0.46) | ATRCYP17A1AAK1GSK3BDYRK1A | |
| SCHEMBL6177797 | 0.81 | CYP17A1 (0.46) | ATRCYP17A1AAK1GSK3BDYRK1A | |
| SCHEMBL13838444 | 0.81 | GRIN2B (0.44) | ATRCYP17A1GSK3BDYRK1AMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450271-B | Ureas, amino and substituted heteroaryl compounds for Cbl-b inhibition | 纽力克斯治疗公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-4003965-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | Nurix Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | CBLB, CBL, CBLC | ATR 712/4885CYP17A1 3746/4885AAK1 1605/4885 |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | ATR 1042/4885CYP17A1 3953/4885AAK1 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.